Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy

被引：0
|
作者：
Qiaoyun Tan
Liyuan Dai
Yanrong Wang
Shuxia Liu
Te Liang
Rongrong Luo
Shasha Wang
Ning Lou
Haizhu Chen
Yu Zhou
Qiaofeng Zhong
Jianliang Yang
Puyuan Xing
Xingsheng Hu
Yutao Liu
Shengyu Zhou
Jiarui Yao
Di Wu
Zhishang Zhang
Le Tang
Xiaobo Yu
Xiaohong Han
Yuankai Shi
机构：
[1] Department of Medical Oncology,
[2] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,undefined
[3] Chinese Academy of Medical Sciences & Peking Union Medical College,undefined
[4] Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs,undefined
[5] State Key Laboratory of Proteomics,undefined
[6] Beijing Proteome Research Center,undefined
[7] National Center for Protein Sciences-Beijing (PHOENIX Center),undefined
[8] Beijing Institute of Lifeomics,undefined
[9] Clinical Pharmacology Research Center,undefined
[10] Peking Union Medical College Hospital,undefined
[11] State Key Laboratory of Complex Severe and Rare Diseases,undefined
[12] NMPA Key Laboratory for Clinical Research and Evaluation of Drug,undefined
[13] Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs,undefined
[14] Chinese Academy of Medical Sciences & Peking Union Medical College,undefined
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Anti-PD1/PDL1 lgG; Subclass; Anti-PD1 IgG4; Biomarker; Anti-PD1 therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1681 / 1691
页数：10
相关论文
共 50 条
  • [21] Bullous pemphigoid under anti-PD1 therapy
    Wirbel, C.
    Milley, S.
    Balme, B.
    Dalle, S.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2020, 147 (11): : 795 - 797
  • [22] Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma
    Simeone, Ester
    Grimaldi, Antonio M.
    Ascierto, Paolo A.
    MELANOMA MANAGEMENT, 2015, 2 (01) : 41 - 50
  • [23] Electronic Nose: An Early Response Biomarker for Anti-PD1 Therapy in Patients with NSCLC
    Muller, Mirte
    Vries, Rianne
    Sterk, Peter
    Baas, Paul
    Van Den Heuvell, Michael
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1306 - S1307
  • [24] Generation of caninized checkpoint inhibitors anti-PD1 and anti-PD-L1 mabs with specific IGG1 and IGG4 canine constant regions for cancer treatment in dogs
    Drakopoulou, P.
    Tsal-Tsalko, A.
    Hofstetter, G.
    Matz, M.
    Karagiannis, S. N.
    Jensen-Jarolim, E.
    Bianchini, R.
    ALLERGY, 2023, 78
  • [25] The Effect of Anlotinib Instead of Glucocorticoids for Encephaledema Induced by Brain Metastases in NSCLC Patients With Anti-PD1/PDL1 Therapy
    Zhuang, H.
    Wang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S399 - S399
  • [26] Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab
    Giovanna Scapin
    Xiaoyu Yang
    Winifred W Prosise
    Mark McCoy
    Paul Reichert
    Jennifer M Johnston
    Ramesh S Kashi
    Corey Strickland
    Nature Structural & Molecular Biology, 2015, 22 : 953 - 958
  • [27] Anti-EMP2 IgG1 combined with anti-PD1/PDL1 antibodies synergistically reduce tumor load in animal models of breast cancer
    Ashki, Negin
    Tsui, Jessica
    Wadehra, Madhuri
    CANCER RESEARCH, 2016, 76
  • [28] Auranofin and the efficacy of anti-PD1 immunotherapy
    Zhang, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] A future boost for anti-PD1 responses
    Stower, Hannah
    NATURE MEDICINE, 2020, 26 (09) : 1331 - 1331
  • [30] A future boost for anti-PD1 responses
    Hannah Stower
    Nature Medicine, 2020, 26 : 1331 - 1331
12345